Mission Therapeutics Revenue and Competitors

Boston, MA USA

Location

$143.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Mission Therapeutics's estimated annual revenue is currently $3.6M per year.(i)
  • Mission Therapeutics's estimated revenue per employee is $77,500
  • Mission Therapeutics's total funding is $143.1M.

Employee Data

  • Mission Therapeutics has 46 Employees.(i)
  • Mission Therapeutics grew their employee count by -30% last year.

Mission Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head ITReveal Email/Phone
3
VP ChemistryReveal Email/Phone
4
Head Clinical Pharmacology & PharmacometricsReveal Email/Phone
5
VP Head OncologyReveal Email/Phone
6
VP Human ResourcesReveal Email/Phone
7
VP, Development OperationsReveal Email/Phone
8
Senior DirectorReveal Email/Phone
9
EVP Development and Chief Medical OfficerReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Mission Therapeutics?

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) ᅢᄁ¬ツᆲ¬タワ an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ᅢᄁ¬ツᆲᅨワNext Kinase Areaᅢᄁ¬ツᆲ¬トᄁ. Missionᅢᄁ¬ツᆲ¬トᄁs DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Missionᅢᄁ¬ツᆲ¬トᄁs strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Missionᅢᄁ¬ツᆲ¬トᄁs leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received ᅢツᅡᆪ87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a ᅢツᅡᆪ1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised ᅢツᅡᆪ60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

keywords:N/A

$143.1M

Total Funding

46

Number of Employees

$3.6M

Revenue (est)

-30%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mission Therapeutics News

2022-04-13 - Acute Kidney Injury Pipeline to Progress with Novel and ...

... Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma,...

2022-03-30 - Mission Therapeutics Authorised to Initiate First Clinical Trial ...

Mission Therapeutics Authorised to Initiate First Clinical Trial for Lead DUB Program, MTX652, in Kidney Disease. March 31, 2022 04:00 AM...

2021-08-09 - Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone

Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone 09-08-2021 Mission Therapeutics, a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (NYSE: ABBV) today announced progression of selected deubiquitylating ...

2021-08-09 - Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone

Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone 09-08-2021 Mission Therapeutics, a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (NYSE: ABBV) today announced progression of selected deubiquitylating ...

2020-07-06 - Mission raises $15m and expands its relationship with Pfizer

Mission raises $15m and expands its relationship with Pfizer 06-07-2020 Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by ex ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.2M46-65%N/A
#2
$6.3M467%N/A
#3
$7.5M4610%N/A
#4
$3.6M4648%$80M
#5
$5.9M46-39%N/A